GeneDx Holdings Corp. is a leading genomics company specializing in genetic testing services for the diagnosis of rare and complex genetic disorders. It provides advanced whole exome and genome sequencing, along with targeted gene panels and microarray testing, to deliver rapid, precise, and actionable clinical insights that inform personalized treatment plans and improve patient outcomes. The company leverages one of the largest rare disease datasets, powered by millions of tests, exomes, genomes, and phenotypic data points, enhanced by AI tools and expert interpretation to achieve higher diagnostic yields than traditional methods. GeneDx supports healthcare providers in addressing conditions such as autism spectrum disorders, developmental delays, epilepsy, cardiomyopathy, and various inherited diseases across pediatric and adult populations. Its offerings facilitate precision medicine by accelerating diagnoses, reducing diagnostic odysseys, and aiding drug discovery through comprehensive genomic analysis. Headquartered in Stamford, Connecticut, GeneDx Holdings Corp. serves clinicians, patients, and health systems seeking to integrate cutting-edge genomics into routine care.